Clinical Trials Study
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Mar 21, 2024; 30(11): 1556-1571
Published online Mar 21, 2024. doi: 10.3748/wjg.v30.i11.1556
Effects of Lactobacillus paracasei N1115 on gut microbial imbalance and liver function in patients with hepatitis B-related cirrhosis
Yan-Chao Hu, Xiang-Chun Ding, Hui-Juan Liu, Wan-Long Ma, Xue-Yan Feng, Li-Na Ma
Yan-Chao Hu, Xiang-Chun Ding, Hui-Juan Liu, Wan-Long Ma, Xue-Yan Feng, Li-Na Ma, Department of Infectious Disease, General Hospital of Ningxia Medical University, Yinchuan 750004, Ningxia Hui Autonomous Region, China
Xiang-Chun Ding, Infectious Disease Clinical Research Center of Ningxia, Yinchuan 750004, Ningxia Hui Autonomous Region, China
Author contributions: Ding XC is the guarantor and designed the study; Hu YC participated in the acquisition, analysis, and interpretation of the data and drafted the initial manuscript; Liu HJ, Ma WL, and Feng XY participated in the acquisition and analysis of the data; and Ding XC and Ma LN critically revised the article for important intellectual content.
Supported by The Health System Research Project of Ningxia Hui Autonomous Region of China, No. 2022-NWKY-061.
Institutional review board statement: The study was reviewed and approved by the Hungarian National Review Board and the Institutional Review Board of the Ningxia Medical University.
Clinical trial registration statement: This study is registered at http://www.chictr.org.cn. The registration identification number is ChiCTRIIR17011061.
Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
Data sharing statement: Technical appendix, statistical code, and dataset available from the corresponding author at [13619511768@163.com]. Participants consent for data sharing was not obtained but the presented data are anonymized and risk of identification is low. No additional data are available.
CONSORT 2010 statement: The authors have read the CONSORT 2010 statement, and the manuscript was prepared and revised according to the CONSORT 2010 statement.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Xiang-Chun Ding, MD, Doctor, Department of Infectious Disease, General Hospital of Ningxia Medical University, No. 804 Shengli Street, Yinchuan 750004, Ningxia Hui Autonomous Region, China. 13619511768@163.com
Received: December 17, 2023
Peer-review started: December 17, 2023
First decision: December 25, 2023
Revised: January 8, 2024
Accepted: March 4, 2024
Article in press: March 4, 2024
Published online: March 21, 2024
Core Tip

Core Tip: Intestinal microbial imbalance and metabolic dysfunction may accelerate the process of liver cirrhosis. We explored the role of probiotic intervention in patients with hepatitis B cirrhosis in this study. After an intervention with the N1115 ready-to-eat Lactobacillus supplement, we found the following significant changes: an increase in gut microbial diversity, structural changes in the microbiota favoring the growth of probiotic microbes, improvements in liver function, and decreases in inflammatory factor levels. We conclude that supplementation with the N1115 ready-to-eat Lactobacillus product may be a beneficial intervention in patients with cirrhosis.